Israeli Protalix Partners With Germany’s Secarna on Rare Kidney Disease Therapies
Israeli Protalix BioTherapeutics partners with Germany’s Secarna Pharmaceuticals to develop rare kidney disease therapies, leveraging AI for drug candidate.
Israeli Protalix BioTherapeutics partners with Germany’s Secarna Pharmaceuticals to develop rare kidney disease therapies, leveraging AI for drug candidate.